We Help Companies Find New Sales Opportunities
GlaxoSmithKline is to create 55 jobs at its penicillin factory in Irvine.
GlaxoSmithKline Research & Development is to relocate its Manchester office to a 10,000 sq ft unit at Exchange Quay.
GlaxoSmithKline has won permission from South Lakeland Council to build a pharmaceuticals plant in Ulverston by 2021, with the creation of 250 jobs.
GlaxoSmithKline has won approval for the £100m expansion of its pharmaceuticals plant in Worthing by 2017.
GlaxoSmithKline is to submit plans for a £25m pharmaceutical ingredients manufacturing plant at its site in Montrose, with the creation of 25 jobs.
GlaxoSmithKline is to sell its oncology products business to Novartis for £8.6bn, and will acquire Novartis' vaccines business for £4.2bn.
GlaxoSmithKline is to invest £200m in the expansion of pharmaceutical plants in Hertfordshire and West Sussex, with the creation of an unspecified number of jobs.
GlaxoSmithKline is to invest £25m in the expansion of its pharmaceuticals plant in Montrose, with the creation of 25 jobs.
GlaxoSmithKline is to recruit 140 apprentices over the next two years, including 16 at its pharmaceuticals plant in Barnard Castle.
GlaxoSmithKline is to sell Lucozade and Ribena, the drink brands made in Gloucestershire by about 500 staff, to Suntory for £1.3bn.
GlaxoSmithKline is considering plans to relocate about 250 research and development jobs from Harlow to sites in Ware and Stevenage next year.
GlaxoSmithKline has raised £172m from the sale of 25 Australian pharmaceutical brands to Aspen Pharmacare.
GlaxoSmithKline is to operate a new £10m medical science research centre at the Olympics testing laboratory in Harlow, with funding from the Medical Research Council and the Department of Health.
GlaxoSmithKline is to acquire US-based Human Genome Sciences for £1.9bn, in order to gain new treatments for lupus, diabetes and heart disease.
GlaxoSmithKline is to buy the Toctino eczema treatment from Basilea of Switzerland for up to £200m, in order to expand its Stiefel dermatology business.
GlaxoSmithKline is to acquire Cellzome, the protein research firm with sites in Cambridge and Germany, for £61m.
GlaxoSmithKline is to invest £500m in the expansion of its pharmaceutical manufacturing facilities in the UK, including a new £350m plant at Ulverston in Cumbria, with the creation of up to 1,000 jobs.
GlaxoSmithKline is to invest a further £18m in a new bottling plant at its drinks plant in Coleford, Gloucestershire, this year.
GlaxoSmithKline has sold a portfolio of over-the-counter medicines to US-based Prestige Brands for £426m.
GlaxoSmithKline has secured a £1.5m Scottish Enterprise grant to expand its research and development facilities in Montrose, with the creation of up to 25 jobs.
GlaxoSmithKline has pledged to expand its pharmaceutical manufacturing and research operations in the UK, in response to government tax incentives.
GlaxoSmithKline is considering sites in Montrose, Irvine and Barnard Castle for the development of a new pharmaceuticals plant, which could create up to 1,000 jobs.
GlaxoSmithKline is to acquire Maxinutrition, the Hemel Hempstead-based supplier of sports drinks and snacks, from Darwin Private Equity for £162m.
GlaxoSmithKline is to acquire Nanjing MeiRui Pharma Co, the Chinese pharmaceuticals manufacturer, for £44m.
GlaxoSmithKline is planning to create up to 1,000 new jobs in the UK, following research tax breaks that will enable it to invest £500m in the expansion of a factory in Hertfordshire and a new biopharmaceuticals plant.
GlaxoSmithKline has acquired Laboratorios Phoenix, the Argentinian pharmaceuticals company, for £172m.
GlaxoSmithKline is looking to create 1,000 new jobs in the UK, as part of a £500m investment in the life sciences sector that follows a government decision to cut taxes on revenues from patents.
GlaxoSmithKline is planning to relocate more than 40 nutritional healthcare research jobs from Coleford to Brentford later this year, and a similar number of jobs will relocate from its site in Slough.
GlaxoSmithKline has confirmed that its Barnard Castle site is one of three potential locations for a new £300m biopharmaceuticals factory, which could create hundreds of jobs.
GlaxoSmithKline is to provide land and facilities worth £11m to a joint venture with the government and Wellcome Trust to build a new £37m bioscience campus in Stevenage, which could create up to 1,500 jobs.
GlaxoSmithKline is to acquire Stiefel Laboratories, the US dermatology company with 3,500 staff, for up to £2.4bn.
GlaxoSmithKline is to acquire a portfolio of more than 50 medicines in Africa, Asia Pacific, Latin America and the Middle East from UCB of Belgium for £486m.
GlaxoSmithKline is to acquire the Pakistan unit of Bristol-Myers Squibb for £25m, including a portfolio of 30 pharmaceutical brands.
GlaxoSmithKline is to acquire AZ Tika, the Swedish supplier of over-the-counter medicines, from AstraZeneca for £146m.
GlaxoSmithKline is planning to invest £50m in the development of a drinks bottling plant at its Coleford site in Gloucestershire by 2011, with the creation of 20 jobs.
GlaxoSmithKline is to acquire Genelabs Technologies, the US biopharmaceuticals company, for £35m.
GlaxoSmithKline is to acquire Biotene, the dry-mouth treatment, from Laclede of the US for £100m, in order to expand its consumer healthcare business.
GlaxoSmithKline has acquired the Egyptian off-patent drugs business of Bristol-Myers Squibb for £120m, including a manufacturing plant and 20 branded products.
GlaxoSmithKline is said to be considering plans to relocate about 800 staff from Greenford to its Stockley Park site in Uxbridge next year.
GlaxoSmithKline is to acquire Sirtris Pharmaceuticals, the US drug discovery company, for £362m.
GlaxoSmithKline is to invest £50m in the development of a new neuroscience research centre at Shanghai in China by the end of next year.
GlaxoSmithKline has acquired Reliant Pharmaceuticals, the US supplier of cardiovascular medicines, for £798m.
GlaxoSmithKline is to acquire Praecis Pharmaceuticals, the US biopharmaceuticals company, for £28m.
GlaxoSmithKline is to acquire Domantis, the Cambridge-based biotechnology research company, for £230m.
GlaxoSmithKline has announced plans to invest £60m in the expansion of its pharmaceuticals factory in Montrose over the next three years, with the creation of up to 150 jobs.
GlaxoSmithKline is to acquire CNS, the US supplier of consumer healthcare products, for £303m.
GlaxoSmithKline is to create 100 new jobs at its pharmaceuticals plant in Montrose over the next few months, in order to expand production of rosiglitazone and carvedilol.
GlaxoSmithKline is to invest £25m at its pharmaceuticals plant in Montrose, securing the future of 250 jobs, having dropped plans to close the site.
GlaxoSmithKline is to acquire the Pliva Research Institute, which has 130 staff, from Pliva of Croatia for up to £29m.
GlaxoSmithKline is said to be considering plans to double its £2.8bn annual research and development budget, although there are no plans for an immediate increase.
GlaxoSmithKline is planning to acquire ID Biomedical Corporation, the Canadian manufacturer of innovative vaccine products, for £0.8bn.
GlaxoSmithKline is to acquire Corixa, the US vaccines manufacturer, for £160m.
GlaxoSmithKline has acquired two heart disease drugs from Sanofi-Synthelabo for £297m, including a manufacturing facility in France that employs 650 staff.
GlaxoSmithKline is planning to set up a £76m medical imaging research centre at Hammersmith Hospital in London, in partnership with Imperial College and the Medical Research Council.
GlaxoSmithKline is donating £750,000 to the Teesdale Enterprise Fund, which aims to create 150 jobs in County Durham by helping new and expanding businesses.
GlaxoSmithKline is to collaborate with Roche of Switzerland on the development of the Ibandronate treatment for osteoporosis, which is expected to reach the market in 2004.